← Back to Search

Anticoagulant

2 for Deep Vein Thrombosis

Phase 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 up to 12 months
Awards & highlights

Summary

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)

Eligible Conditions
  • Deep Vein Thrombosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
Secondary outcome measures
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation
+17 more

Side effects data

From 2018 Phase 4 trial • 557 Patients • NCT01884337
7%
Incision site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
TOTAL KNEE REPLACEMENT (TKR)
TOTAL HIP REPLACEMENT (THR)

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: 2Experimental Treatment1 Intervention
5.0 mg
Group II: 1Experimental Treatment1 Intervention
2.5 mg
Group III: 3Active Control1 Intervention
0 mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apixaban
FDA approved

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,678 Previous Clinical Trials
4,122,934 Total Patients Enrolled
9 Trials studying Deep Vein Thrombosis
22,997 Patients Enrolled for Deep Vein Thrombosis
PfizerIndustry Sponsor
4,625 Previous Clinical Trials
14,281,483 Total Patients Enrolled
9 Trials studying Deep Vein Thrombosis
1,022,495 Patients Enrolled for Deep Vein Thrombosis
~156 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top